The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario
Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods....
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2016/6279250 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558956688441344 |
|---|---|
| author | Haris M. Vaid Ximena Camacho John T. Granton Muhammad M. Mamdani Zhan Yao Samantha Singh David N. Juurlink Tara Gomes |
| author_facet | Haris M. Vaid Ximena Camacho John T. Granton Muhammad M. Mamdani Zhan Yao Samantha Singh David N. Juurlink Tara Gomes |
| author_sort | Haris M. Vaid |
| collection | DOAJ |
| description | Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario’s publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n=251). Combination therapy was used to treat 22.9% (n=69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96–$747) for those who survived and $2,021 (IQR $993–$6,399) for those who died over a one-year period, respectively (p<0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management. |
| format | Article |
| id | doaj-art-c4e5723769f64e859e128d69841f554b |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-c4e5723769f64e859e128d69841f554b2025-02-03T01:31:17ZengWileyCanadian Respiratory Journal1198-22411916-72452016-01-01201610.1155/2016/62792506279250The Characteristics of Treated Pulmonary Arterial Hypertension Patients in OntarioHaris M. Vaid0Ximena Camacho1John T. Granton2Muhammad M. Mamdani3Zhan Yao4Samantha Singh5David N. Juurlink6Tara Gomes7School of Medicine, Queen’s University, 15 Arch Street, Kingston, ON, K7L 3N6, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaToronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaThe Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, CanadaBackground. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario’s publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n=251). Combination therapy was used to treat 22.9% (n=69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96–$747) for those who survived and $2,021 (IQR $993–$6,399) for those who died over a one-year period, respectively (p<0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management.http://dx.doi.org/10.1155/2016/6279250 |
| spellingShingle | Haris M. Vaid Ximena Camacho John T. Granton Muhammad M. Mamdani Zhan Yao Samantha Singh David N. Juurlink Tara Gomes The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario Canadian Respiratory Journal |
| title | The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario |
| title_full | The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario |
| title_fullStr | The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario |
| title_full_unstemmed | The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario |
| title_short | The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario |
| title_sort | characteristics of treated pulmonary arterial hypertension patients in ontario |
| url | http://dx.doi.org/10.1155/2016/6279250 |
| work_keys_str_mv | AT harismvaid thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT ximenacamacho thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT johntgranton thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT muhammadmmamdani thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT zhanyao thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT samanthasingh thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT davidnjuurlink thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT taragomes thecharacteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT harismvaid characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT ximenacamacho characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT johntgranton characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT muhammadmmamdani characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT zhanyao characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT samanthasingh characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT davidnjuurlink characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario AT taragomes characteristicsoftreatedpulmonaryarterialhypertensionpatientsinontario |